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ABSTRACT: Rippling muscle disease is caused by muta-
tions in the gene encoding caveolin-3 (CAV3), the
muscle-specific isoform of the scaffolding protein caveo-
lin, a protein involved in the formation of caveolae. In
healthy muscle, caveolin-3 is responsible for the forma-
tion of caveolae, which are highly organized sarcolemmal
clusters influencing early muscle differentiation, signal-
ling and Ca
21 homeostasis. In the present study we
examined Ca
21 homeostasis and excitation–contraction
(E-C) coupling in cultured myotubes derived from two
patients with Rippling muscle disease with severe
reduction in caveolin-3 expression; one patient har-
boured the heterozygous c.84C4A mutation while the
other patient harbored a homozygous splice-site mutation
(c.1021 2T4C) affecting the splice donor site of intron
1 of the CAV3 gene. Our results show that cells from
control and rippling muscle disease patients had similar
resting [Ca
21]i and 4-chloro-m-cresol-induced Ca
21
release but reduced KCl-induced Ca
21 influx. Detailed
analysis of the voltage-dependence of Ca
21 transients
revealed a significant shift of Ca
21 release activation to
higher depolarization levels in CAV3 mutated cells. High
resolution immunofluorescence analysis by Total Internal
Fluorescence microscopy supports the hypothesis that
loss of caveolin-3 leads to microscopic disarrays in the
colocalization of the voltage-sensing dihydropyridine
receptor and the ryanodine receptor, thereby reducing
the efficiency of excitation–contraction coupling.
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Introduction
Rippling muscle disease (RMD; MIM] 606072) is a rare
autosomal dominant disorder caused by mutations in CAV3
(MIM] 601253) the gene encoding caveolin-3 (CAV3), a caveolin
isoform exclusively expressed in skeletal, cardiac, and smooth
muscles [Betz et al., 2001; Woodman et al., 2004]. Caveolins are
small 22-kDa transmembrane proteins that homo-oligomerize on
the plasma membrane giving rise to caveolae, or invaginated
structures of 50–100nm in diameter (for recent reviews, see
[Cohen et al., 2004; Hansen and Nichols, 2010; Hnasko and
Lisanti, 2003]). In skeletal muscle numerous proteins including
b-dystroglycan, nitric oxide synthase, phosphofructokinase, tubu-
lin, cadherin-M converge within sarcolemmal caveolae [Galbiati
et al., 2001; Garcı ´a-Cardena et al., 1997; Song et al., 1996; Sotgia
et al., 2000, 2003; Volonte et al., 2003), whereas in mature muscle
fibers, caveolins are also distributed in the subsarcolemmal space
on the neck of the T-tubules, where ion channels, pumps, kinases,
and signaling molecules collect [Kristensen et al., 2008; Lamb,
2005; Murphy et al., 2009; Scriven et al., 2005]. Besides
functioning as a converging molecule, CAV3 is involved in
myoblast differentiation, survival, and cell fusion, and its
transcription level increases early in development during muscle
tissue differentiation [Galbiati et al., 2001; Volonte et al., 2003].
Experiments on zebrafish have demonstrated that injection of
embryos with CAV3 antisense morpholinos results in embryos
with uncoordinated movements probably due to disorganized
fused myoblasts, chaotic filament bundles of the contractile
proteins, dispersed mitochondria and poorly developed T-tubules
[Nixon et al., 2005].
Although their exact physiological role is not clear, the above
data indicate that caveolin-3 plays an important role in muscle
function and mutations in CAV3 have indeed been linked to
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Muscular Dystrophy (LGMD; MIM] 607801), Rippling Muscle
Disease (RMD; MIM] 606072), Distal myopathy (DM; MIM]
601253), and HyperCKemia [Betz et al., 2001; Gazzerro et al.,
2010; Woodman et al., 2004]. In some cases, mutations in CAV3
have also been associated with cardiomyopathy [Calaghan and
White, 2006; Catteruccia et al., 2009; Hayashi et al., 2004; Vatta
et al., 2006]. CAV3 maps on human chromosome 3p25 and is
made up of two exons; so far, 24 missense mutations, 1-bp
insertion, 3-bp deletions, a splice-site substitution, and a genomic
macro deletion have been reported in patients with caveolino-
pathies [Aboumousa et al., 2008; Woodman et al., 2004]. Most
mutations are inherited in a dominant way and lead to a severe
decrease in the expression of all CAV3, because mutated and wild-
type proteins multimerize within the Golgi, where they form a
complex that is tagged for proteolysis and degraded in the
proteosome leading to very low levels of expression of caveolin-3
on the sarcolemma [Cohen et al., 2004; Galbiati et al., 1999].
CAV3 is made up of 151 amino acids, of which the first 55 residues
constitute the NH2 terminus, residues 56–73 make up the
scaffolding domain important in homo-oligomerization, residues
76–108 form the transmembrane domain that gives rise to a hair
loop structure, allowing the COOH- and NH2-teminus to face the
same side of the membrane [Cohen et al., 2004; Galbiati et al.,
2001]. Mutations found in patients are more frequent in the NH2
domain, followed by the scaffolding and membrane domains
[Aboumousa et al., 2008; Woodman et al., 2004]. Interestingly,
clinical evidences have demonstrated that the same CAV3 mutation
in different populations and even within the same family, can result
in a different clinical phenotype, indicating the influence of
additional factor(s) in the phenotypic outcome of the mutation.
Recently, Fischer et al. [2003] identified a mutation in CAV3 in
a large German family. This family harbored the c.84C4A
heterozygous substitution leading to the p.D28E mutation.
Another German family was subsequently identified harboring
an autosomal recessive splice site mutation c.1021 2T4Ci n
intron 1 [Mu ¨ller et al., 2006]; both mutations lead to drastically
reduced levels of expression of CAV3 in the skeletal muscle. The
patient harboring the p.D28E mutation had clear signs of RMD
characterized by percussion-induced rapid muscle contraction
and muscle mounding, painful muscle cramping, elevated creatine
kinase levels, and hypertrophic calves [Fischer et al., 2003],
whereas the patient harboring the splice-site mutation had muscle
weakness, elevated creatine kinase levels, percussion-induced
muscle mounding, and mild myopathic degeneration with
fiber-size variation and an increase of connective tissue [Mu ¨ller
et al., 2006].
Although the precise pathomechanism is still elusive, a number
of reports have indicated that CAV3 may have a role in Ca
21
homeostasis [Calaghan and White, 2006; Kamishima et al., 2007;
Weiss et al., 2008], and it has been shown that expression of
mutated caveolin in muscle cells alters the function of the
dihydropyridine receptor (DHPR) [Couchoux et al., 2007]. More
recently, it was demonstrated that CAV3 interacts directly with the
ryanodine receptor (RyR1) sarcoplasmic reticulum Ca
21 release
channel [Vassilopoulos et al., 2010]. In the present report we
studied excitation–contraction coupling in human skeletal muscle
myotubes obtained from the two patients harboring the above-
described CAV3 mutations. Our results show that the myotubes
from control or RMD patients have similar resting [Ca
21]a n d
ryanodine receptor-activated Ca
21 release. Interestingly however,
cells bearing the mutated CAV3 showed a shift in depolarization-
induced Ca
21 release and a decreased depolarization-induced Ca
21
influx, suggesting that lack of caveolin leads to a less efficient
excitation–contraction coupling.
Materials and Methods
Mutation Nomenclature
Nucleotide numbering for CAV3 reflects cDNA numbering with
11 corresponding to the A of the ATG translation initiation
codon in the reference sequence (GenBank NM_033337.1),
according to journal guidelines (www.hgvs.org/mutnomen). The
initiation codon is codon 1.
Primary Skeletal Muscle Cultures
Primary skeletal muscle cultures were established from
fragments of muscle biopsies obtained from patients undergoing
diagnostic testing, as previously described [Ducreux et al., 2004].
Cells were cultured on 0.17-mm thick glass coverslips in growth
medium and induced to differentiate into myotubes by culturing
them in DMEM plus 4.5mg/ml glucose, 0.5% bovine serum
albumin (BSA), 10ng/ml EGF, 0.15mg/ml creatine, 5ng/ml
insulin, 200mM glutamine, 600ng/ml penicillin G and strepto-
mycin, and 7mM HEPES, pH 7.4 for 7–10 days.
Cytoplasmic Calcium Measurements
Coverslip grown myotubes were loaded with the fluorescent
ratiometric Ca
21 indicator fura-2-AM (final concentration 5mM)
in differentiation medium for 30min at 371C, after which the
coverslips were mounted onto a 371C thermostatically controlled
chamber that was continuously perfused with Krebs-Ringer
medium. On-line measurements were recorded using a fluorescent
Axiovert S100 TV inverted microscope (Carl Zeiss GmbH, Jena,
Germany) equipped with a 20  water-immersion FLUAR
objective (0.17 NA), filters (BP 340/380, FT 425, BP 500/530),
and attached to a Hamamatsu multiformat CCD camera. Images
were acquired at 1-sec intervals and the exposure time was fixed at
100msec for both (340- and 380-nm excitation) wavelengths.
Changes in fluorescence were analyzed using an Openlab imaging
system and the average pixel value for each cell was measured at
excitation wavelengths of 340 and 380nm as previously described
[Ducreux et al., 2004]. Individual cells were stimulated by
means of a 12- or 8-way 100mm diameter quartz micro-
manifold computer controlled microperfuser (ALA Scientific
instruments, Westbury, NY), as previously described [Ducreux
et al., 2004].
Ca21 Influx by TIRF Microscopy
Depolarization-induced Ca
21 influx was monitored by TIRF
microscopy (total internal fluorescent microscopy) in myotubes
loaded with fluo-4-AM. Briefly, glass coverslips grown and
differentiated human myotubes were mounted on a thermostated
perfusion chamber, bathed continuously in Krebs-Ringer buffer.
Excitation-coupled Ca
21 entry (ECCE) [Bannister et al., 2009;
Cherednichenko et al., 2004] was measured after application of
60mM KCl to myotubes pretreated with 100mM ryanodine to
block RyR1-mediated Ca
21 release. On-line fluorescence images
were acquired using an inverted Nikon TE2000 TIRF microscope
equipped with an oil immersion CFI Plan Apochromat 60  TIRF
objective (1.49 N.A.) and an electron multiplier Hamamatsu CCD
camera C9100-13, which allows fast data acquisition, as previously
310 HUMAN MUTATION, Vol. 32, No. 3, 309–317, 2011described [Treves et al., 2010]. Our TIRF microscope is equipped
with a surface reflective interference contrast (SRIC) cube to
identify the focal plane corresponding to the coverglass/cell
membrane contact prior to TIRF acquisition. The focus was
maintained at the coverglass/cell membrane contact by using the
perfect focus system (PFS) that exploits an infrared laser beam
and a quadrant diode for the online control of the micro-
scope’s focusing motor. Fluo-4-loaded cells were excited with a
solid-state laser beam at 488nm and the emitted fluorescence
was collected through a 520 narrow band filter. Data were
analyzed using Metamorph imaging software (Molecular Devices,
Menlo Park, CA).
Electrophysiological Measurements and Confocal Ca21
Imaging
Human myoblasts were grown on laminin-coated glass cover-
slips and differentiated into myotubes. Cells were voltage-clamped
in the whole-cell patch clamp configuration with low resistance
borosilicate glass micropipettes (1–3MO) using an Axopatch 200B
amplifier (Axon Instruments, Union City, CA) controlled by a
custom-written data-acquisition software developed by LabView
(National Instruments, Austin, TX). The pipette solution
contained (in mM) 100 CsAsp, 20 tetraethylammonium(TEA)-
Cl, 10 HEPES, 5 MgCl2,5N a 2ATP, 0.05 EGTA, 0.1 K5-Fluo-3
at pH 7.2 (adjusted with CsOH). External solution contained
(in mM) 130 CsCH3SO3, 2 MgCl2, 2 CaCl2, 10 Glucose, 20 HEPES
at pH 7.4 (adjusted with CsOH). The voltage protocol consisted of
stepwise depolarizations (50msec) from a holding potential of
 80mV to increasing potentials from  60mV to 110mV.
Activation of the voltage-dependent dihydropyridine receptor
(skeletal DHPR CaV1.1) triggered Ca
21 release from the SR via
electromechanical coupling between DHPR and RyR1. Changes in
[Ca
21]i were simultaneously recorded with membrane currents
using the fluorescent Ca
21 indicator K5-Fluo-3 (Biotium, Haward,
CA) and a laser-scanning confocal microscope (MicroRadiance,
BioRad, Hercules, CA) with a 60  water immersion objective
lens. Fluo-3 was excited at 488nm with an argon ion laser, and
emitted light was collected above 500nm. Linescan images were
recorded at a rate of 500lines/sec. Confocal images were analyzed
in ImageSXM (free software based on NIH Image) [Barrett, 2002]
and further processed together with the voltage clamp data using
IgorPro (Wavemetrics, Lake Oswego, OR). Changes in [Ca
21]i are
expressed as changes in fluorescence (DF/F0). All measurements
have been performed at room temperature.
Western Blotting
Total muscle homogenate and SR fraction obtained from
skeletal muscle leftover fragments that had been stored in liquid
N2 were isolated. Proteins were separated by SDS PAGE, blotted
onto nitrocellulose, and probed with antibodies against caveolin-3
(GeneTex Inc., Irvine, CA; catalog No. GTX109650), RyR1
(Thermo Scientific, West Palm Beach, CA; catalog No. MA3-
925), a1.1 subunit of the DHPR (Santa Cruz, Santa Cruz, CA;
sc- 8160), SERCA2 (Santa Cruz, sc-8095), calsequestrin [Delbono
et al., 2007], and glycogen phosphorylase (Santa Cruz, sc-4634),
followed by peroxidase-conjugated secondary antibodies. Bands
were visualized by chemiluminescence, using the Super Signal
West Dura kit from Thermo Scientific. For comparison, the
intensities of the immunoreactive bands were quantified by
densitometry using Bio-Rad GelDoc 2000; intensities were
corrected for glycogen phosphorylase (total muscle homogenate)
and calsequestrin (total SR).
Immunofluorescence Analysis
Glass coverslips grown and differentiated myotubes were fixed
in an ice-cold solution of acetone:methanol (1:1) for 20min,
rinsed two times with phosphate-buffered saline (PBS), and
blocked with 10% blocking buffer (Roche Applied Science,
Indianapolis, IN) for 60min at room temperature. Coverslips
were incubated with goat anti-a1.1 subunit of the DHPR (final
concentration 10mg/ml) and mouse anti-RyR (final concentration
10mg/ml) in PBS; after 60min coverslips were rinsed three times
5min each with PBS and incubated with donkey anti-goat FITC
(Santa Cruz) for 60min, extensively washed with PBS, and
incubated with Alexa Fluor405 conjugated goat anti-mouse IgG
(Invitrogen). After 60min coverslips were washed and mounted in
glycerol mounting medium. Fluorescence was visualized through a
100  oil immersion CFI Plan Apochromat TIRF objective (1.49
NA), by exciting at 488 (Sapphire laser) to visualize FITC, and at
405nm using a laser from Coherent Laboratories (Coherent Labs
Inc., Santa Clara, CA). AlexaFluor 405 fluorescence was visualized
using a BrightLine CH 427 filter (AHF Analysentechnir AG,
Tubingen, Germany). Colocalization analysis of a 1.1 of the
DHPR and RyR was performed using the colocalization applica-
tion included in the Metamorph 5.7.4 software package as
previously described [Treves et al., 2010]; only myotubes with
more than two nuclei were analyzed.
Statistical Analysis
Statistical analysis was performed using the Student’s t-test
for paired samples; means were considered statistically significant
when the P-value was o0.05. The Origin computer program
(Microcal Software, Inc., Northampton, MA) was used for
statistical analysis.
Results
The aim of the present report is to assess whether mutations in
CAV3 lead to dysregulation of Ca
21 homeostasis in human muscle
cells. In order to assess this we first monitored whether the
absence/reduced levels of CAV3 affects the expression levels of the
main components of the excitation–contraction (E-C) coupling
machinery, namely, the DHPR and the RyR calcium channels,
calsequestrin and the SERCA Ca
21 pump [Treves et al., 2009].
Figure 1A shows Western blot analysis of total muscle homogenate
(CAV3, RyR1, DHPR) and of the total sarcoplasmic reticulum
(SR) fraction (SERCA2, calsequestrin) obtained from muscle
biopsy fragments of the patients harboring CAV3 mutations and
controls. As shown previously [Fischer et al., 2003; Mu ¨ller et al.,
2006], the amount of CAV3 present in the muscle homogenate of
both patients is greatly reduced. Interestingly, no significant
differences were found in the amounts of RyR1, DHPR a1.1,
SERCA2, and calsequestrin expressed in the muscle biopsy from
these patient compared to that expressed in control biopsies.
Thus, the absence of caveolin-3 does not grossly alter the
expression level of the protein components involved in Ca
21
homeostasis.
We next studied the Ca
21 homeostasis of the myotubes from the
two patients with RMD. Although myotubes were obtained from
the two patients with different mutations, as shown in Figure 1A
and reported for other CAV3 mutations [Aboumousa et al., 2008;
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substitutions resulted in a drastic reduction of CAV3 expression.
Because of this and because Western blot analysis revealed similar
levels of expression of the main protein components involved in
E-C coupling (Fig. 1), we pooled the results obtained on Ca
21
homeostasis on the myotubes from the two patients. Figure 2
shows that the mean resting fluorescent ratio and the peak Ca
21
release obtained by stimulating the cells with maximal amounts of
Figure 1. Western blot analysis of skeletal muscle proteins in muscle biopsies from the two RMD patients harboring CAV3 mutations.
Proteins (30mg) in the total muscle homogenate (CAV3, a1.1 DHPR, RyR1 and glycogen phosphorylase) or total SR fraction (20mg) (SERCA2 and
calsequestrin) were blotted onto nitrocellulose and probed with the indicated antibodies as specified in the Methods section. The relative
expression levels of the immunopositive bands in the biopsy from the RMD patient harboring the c.84C4A mutation (left) and the homozygous
splice-site mutation c.1021 2T4C (right) were compared to that of control biopsies that were considered 100%; intensity values were estimated
by densitometric analysis of the indicated number of blots and normalized with respect to the band intensity of glycogen phosphorylase (total
homogenate) or calsequestrin (SR). Bars represent mean7SEM of n experiments; Po0.0001.
Figure 2. Characterization of cytoplasmic Ca
21 homeostasis in myotubes with CAV3 deficiency. Calcium imaging was performed in fura-2
loaded myotubes as described in the Methods section. A: Mean (7SEM of n558 and 92 for control and RMD, respectively) resting [Ca
21]
(expressed as fluorescence intensity ratio 340/380nm) was not different in control and RMD myotubes. B: Mean (7SEM) peak Ca
21 increase
induced by the addition of 100mM KCl (inducing depolarization) and 600mM 4-chloro-m-cresol (4-cmc, RyR1 agonist) in the presence of Krebs-
Ringer medium (KR) containing 100mML a
31. Open boxes, control myotubes; gray boxes, myotubes from CAV3 deficient myotubes (n57–15
measurements). C: Traces showing fura-2 change in fluorescence (ratio 340/380nm) of individual myotubes from a control and a CAV3 mutation-
bearing patient in response to 100mM KCl and 600mM 4-cmc.
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cresol (which directly activates the RyR1) [Zorzato et al., 1993]
were not significantly different between control myotubes and
myotubes from the two patients with RMD when the experiments
were performed in Krebs Ringer 1100mML a
31, a general Ca
21
channel blocker used to prevent any contaminating Ca
21 influx.
Panel C shows representative traces of Ca
21 release experiments
performed in the presence of contaminating Ca
21 plus 100mM
La
31. These results indicate that the lack of CAV3 does not grossly
affect RyR1-mediated Ca
21 release from the intracellular stores.
A more detailed investigation of the electromechanical coupling
in control and RMD myotubes, however, revealed significant
differences in the voltage-dependent Ca
21 release properties of
cells from RMD patients. Using an electrophysiological approach
combined with confocal Ca
21 imaging we studied Ca
21 release
induced by membrane depolarization. Figure 3A shows original
paired sample traces for current (lower trace) and Ca
21 transient
(upper trace) in control human myotubes at increasing levels of
membrane depolarization (for representative current traces see
Supp. Fig. S1). As expected, increasing depolarization results in an
increase in Ca
21 release, which saturates as the depolarizing
voltage pulse reaches  10mV. Figure 3B shows the line profiles
and corresponding linescan images of the Ca
21 response to a
depolarizing step from  80 to  20mV in control (upper black
trace) and RMD myotubes (lower red trace), respectively. At the
same trigger potential, RMD myotubes present lower voltage-
induced Ca
21 release amplitudes from the SR when compared
with control cells. The voltage-dependence of Ca
21 release is
summarized in Figure 3C; normalized peak Ca
21 release
amplitudes are plotted as a function of the test potential.
The membrane potentials at half maximal Ca
21 release (V1/2)
are indicated revealing a significant shift (Po0.05) in V1/2 from
 29.471.8mV in control myotubes to  24.773.2 in RMD
myotubes. This right shift in V1/2 is further accompanied by a
shift in the maximal Ca
21 transient amplitude from  10mV in
control to 0mV in RMD myotubes. These results indicate that
depletion of CAV3 reduces the coupling efficiency between the
DHPR and the RyR.
Recently it was shown that in skeletal muscle myotubes, plasma
membrane depolarization is accompanied by Ca
21 influx, which is
mediated by the DHPR and has been defined as excitation coupled
Ca
21 entry (ECCE) [Bannister et al., 2009; Cherednichenko et al.,
2004]. Although the functional significance of this Ca
21 influx is
currently unknown, it depends on the presence of both the RyR1
and DHPR. Becausev (1) depolarization-induced Ca
21 release is
affected by the loss CAV3 (Fig. 3) [Couchoux et al., 2007], (2)
studies by Vassilopoulos et al. [2010] demonstrated a direct
interaction between CAV3 and the RyR1, and (3) ECCE depends
on the presence of the DHPR and of the RyR, we studied ECCE in
the myotubes from the two RMD patients. Figure 4 summarizes
the pooled results obtained by TIRF microscopy on Ca
21 influx
activated by 60mM KCl. As indicated in the Methods section,
myotubes were pretreated with 100mM ryanodine to block Ca
21
release from the SR via RyR1 [Meissner, 1986]. The bottom trace
in Figure 4B (.-.-.-) and the inset in Figure 4C show that in the
absence of extracellular Ca
21 (and in the presence of 100mM
La
31) the addition of 60mM KCl does not lead to a change in
fluo-4 fluorescence, confirming that the increase in Fluo-4 is not
due to calcium release from the SR. When the experiments were
conducted in the presence of 2mM Ca
21, on the other hand, the
addition of KCl was accompanied by a transient increase in Fluo-4
fluorescence, confirming that this fluorescence increase represents
Figure 3. Voltage-dependence of Ca
21 transients in control and RMD myotubes. Cells were patch-clamped and held at a holding potential
(VH)o f 80mV. A: Paired sample traces of current (lower trace) and Ca
21 release recordings (upper trace) at different test potentials (from  40
to 0mV) in a fluo-3 loaded control myotube. Depolarizations (50msec) to increasing membrane potentials activated Ca
21 release from the SR.
B: Comparison of Ca
21 release during a depolarizing step to  20mV in control (black) and Cav-3 deficient RMD (red) myotubes. Linescan
images and line profiles show the reduced Ca
21 transient amplitude in caveolin-3 deficient RMD myotubes at same trigger voltage when
compared with control. C: Summary of the voltage-dependence of Ca
21 release in control (WT, n510) and caveolin-3-deficient RMD myotubes
(n58). Ca
21 transient amplitudes have been normalized to the maximal release amplitude in each cell. Membrane potentials at half-maximal
activation (V1/2) indicate a right shift of the voltage-dependence in RMD myotubes (Po0.05).
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21 influx from the extracellular medium. We then compared
the extent of the KCl-activated Ca
21 influx in myotubes from the
two RMD patients to that observed in myotubes from controls.
The traces in Figure 4B and bar graph plots in Figure 4C show that
myotubes from the RMD patients have a significantly smaller
(twofold) Ca
21 influx peak compared to that obtained in control
myotubes.
Because the lack of CAV3 is not accompanied by gross
alterations in the expression levels of the RyR and DHPRs, the
above results indicate that the lack of this protein may affect the
Figure 4. TIRF measurements of Ca
21 influx induced by 60mM KCl in human myotubes. A: Myotubes from a control patient were visualized
by brightfield (top left panel), with a surface reflection interference contrast (SRIC) filter to visualize and fix the focal plane of the coverglass/cell
membrane interphase (top central panel). Next panels show pseudocolored ratiometric images (peak fluorescence after addition of KCl/ resting
fluorescence) of fluo-4 fluorescence changes at the indicated time-points after application of KCl. Fluorescence was monitored through a 60 
TIRF objective and analyzed using Metamorph as detailed in the Methods section. Bar indicates 30mm.B :Representative traces from ECCE
showing changes in fluo-4 fluorescence in a myotube from a control individual (_____) and a patient harbouring a CAV3 mutation (yy.)
stimulated with 60mM KCl in the presence of 2mM Ca
21 or myotubes from a control in the absence of added Ca
21 and in the presence of
100mML a
31 (.-.-.-.-.). TIRF measurements were performed as indicated in the Methods section in myotubes pretreated with 100mM ryanodine.
C: Bar graph depicting mean (7SEM) peak increase of fluo-4 fluorescence induced by 60mM KCl in control and caveolin-3 deficient myotubes
in the presence of 2mM Ca
21. Insert shows the mean (7SEM) peak fluo-4 fluorescence increase of control myotubes in the presence of
100mML a
31 (gray bar) or 2mM Ca
21 (empty bar).
Figure 5. Coimmunolocalization of the a1.1 subunit DHPR and RyR1 by immunofluorescence analysis by TIRF microscopy in human myotubes
from a control individual. Myotubes were visualized using an inverted Nikon TE2000 TIRF microscope equipped with a CFI Plan Apochromat
100  TIRF objective (1.49 NA). Left panel shows photomicrograph of cells through a SRIC filter; central left panel shows the same cells excited
with a Sapphire laser at 488nm (a1.1 subunit of the DHPR; green fluorescence); central right panel shows photomicrograph of the same cells
excited at 405 and visualized through a BrightLine CH 427 filter (RyR; dark blue fluorescence). Right panel, merged images using the ‘‘color-
combine’’ option included in the Metamorph software package. Arrows indicate overlapping pixels (light blue). Bar indicates 10mm.
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21 channels on their
respective membranes. To to verify this, we performed immuno-
fluorescence analysis of the distribution of the DHPR and RyR
in TIRF mode. Figure 5 shows a representative photomicrograph
of a myotube from a control individual observed with a SRIC
filter to show that the selected focal plane is at the glass coverslip/
membrane interface (left). This focal plane was fixed through
the perfect focus system and imunofluorescence analysis was
subsequently performed. The central left and right panels of
Figure 5 show the punctuated fluorescent distribution of the
DHPRa1.1 and RyR on or within 100nm of the plasma
membrane, and the panel on the right shows the merged images
revealing areas of colocalization (arrows). Table 1 shows the
results of detailed colocalization analysis (n510 cells): the
lack of CAV3 caused a 30% reduction in the area of
overlap between the RyR and the DHPR; this was due to a
relative increase in the distribution of RyRs in areas not containing
DHPRs.
Discussion
In the present study we investigated whether severe reduction of
CAV3 as seen in two patients with RMD affects E-C coupling, the
physiological process whereby an electrical signal, the depolariza-
tion of the muscle fibre, is converted into a chemical signal, that is,
release of Ca
21 from the sarcoplasmic reticulum, leading to
muscle contraction and force development [Fleischer and Inui,
1989; Rios and Pizarro, 1991]. This process depends on the fine
micro architecture underlying the calcium release unit whereby
the voltage sensing DHPR present on T-tubules faces ordered
arrays of RyR1 on the SR junctional membrane [Franzini-
Armstrong and Jorgensen, 1994]. Mutations in genes encoding
several proteins involved in E-C coupling and Ca
21 homeostasis
have been shown to be linked to neuromuscular disorders such as
Central core disease, multi-minicore disease, Centronuclear myo-
pathy, King Denborough syndrome, and Malignant Hyperthermia
[Treves et al., 2005; Wilmshurst et al., 2010; Zhou et al., 2007]. We
obtained myotubes from one patient with a homozygous splice
site mutation leading to very low levels of caveolin-3 wild-type
transcript [Mu ¨ller et al., 2006]. The other patient harbored the
heterozygous p.D28E substitution and also expressed very low
levels of caveolin-3; although substitution of an aspartic acid
residue for a glutamic acid residue may seem of minor
consequence because the two amino acids are negatively charged,
mutagenesis studies on other proteins have indicated that such
substitutions can lead to protein instability by causing structural
perturbations [Mizrahi et al., 1994]. Thus, although the patients
harbored different substitutions and had different clinical
symptoms, both exhibited a severe reduction in the amount of
CAV3 expressed. Thus, by pooling the functional data obtained on
myotubes from the two patients, we studied the effect of CAV3
depletion, irrespective of the compensatory mechanisms activated
by the patient. The results on cytoplasmic Ca
21 homeostasis
reveal that the absence of CAV3 does not cause significant
alterations of E-C coupling in myotubes and are in agreement
with those obtained by Weiss et al. [2008], who showed that loss
of caveolin does not affect either the resting [Ca
21]o r
depolarization-induced peak Ca
21 release in mouse skeletal
muscle cells. A deeper investigation into the electromechanical
coupling of caveolin-3-depleted cells, however, revealed a 5-mV
shift in the V1/2 activating potential, resulting in reduced Ca
21
release at low depolarizing potentials. Although different from
what was reported in mouse skeletal muscle [Weiss et al., 2008],
these results support the findings of Calaghan and White [2006]
on rat ventricular myocytes treated with methyl-b-cyclodextrin to
disrupt caveolae. In the latter cell type removal of CAV3 resulted
in a reduced SR fractional Ca
21 release, indicating a loss in E-C
coupling efficiency. Thus, as recently suggested by Dart [2010],
lipid microdomains may be involved in the fine regulation of ion
channels and alterations in the properties and composition of the
lipids or alterations in the distribution of caveolins may affect
channel gating kinetics, trafficking, and surface expression of
proteins [Edelman and Lisanti, 2001].
We were interested in investigating whether the reduced E-C
coupling efficiency in CAV3 mutated cells might have downstream
effects. In fact, in a recent study Murata et al. [2007] showed that
caveolin-1 is essential for Ca
21 entry in endothelial cells; upon
stimulation with acetylcholine endothelial cells from caveolin-1
KO mice have a ‘‘normal’’ peak Ca
21 transient but a 50% reduc-
tion in agonist invoked Ca
21 entry. In skeletal muscle cells, E-C
coupling is thought to be essentially independent of extracellular
Ca
21 [Armstrong et al., 1972]. However, a number of recent
studies have revealed that activation of the DHPR Ca
21 channel
is accompanied by influx of Ca
21 [Bannister et al., 2009;
Cherednichenko et al., 2004], especially during long depolariza-
tion. This phenomenon requires the physical presence of the
DHPR and RyR1 and is enhanced in cells bearing RyR1 mutations
linked to Malignant Hyperthermia [Cherednichenko et al., 2009;
Yang et al., 2007]. We found that muscle cells from RMD patients
had a 50% reduction in KCl induced Ca
21 influx. Western blot
analysis revealed no significant differences in the level of
expression of DHPR or RyR1; thus, the reduced ECCE is
apparently not due to lack of the proteins responsible for the Ca
21
influx. One possibility that would explain how the lack of CAV3
decreases ECCE is that lack of CAV3 affects the distribution of the
DHPR and RyR1 on their respective membranes. A hypothesis
supported by the colocalization experiments performed in TIRF
mode as well as by recent results by Vassilopoulos et al. [2010],
who showed that RyR1 and caveolin-3 coimmunoprecipitate and
that caveolin-3 interacts directly with a transmembrane domain of
the RyR1. Thus, the lack of CAV3 seems to derange the
microarchitecture of the main protein components of the E-C
coupling machinery leading (1) to a less efficient coupling,
particularly evident at low depolarizing stimuli and (2) to a
decrease in ECCE. We are aware that the TIRF experiments were
performed on myotubes and theoretically the colocalization
results could reflect a different degree of differentiation of cells
from control and RMD patients. To minimalize this possibility, we
Table 1. Colocalization by TIRF Microscopy of the DHPR and RyR in Myotubes from Controls and CAV3
  Individuals
Cell phenotype % Area RyR over DHPR % Area RyR not over DHPR % Area DHPR over RyR % Area DHPR not over RyR
Control 52.674.2 47.474.2 30.473.9 69.773.9
RMD (caveolin-3
 ) 36.974.8
a 63.174.8
a 28.076.2 71.976.8
Colocalization was performed as described in the Materials and Methods section using the ‘‘colocalization’’ option included in the Metamorph 5.7.4 software package.
aPo0.03.
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support of our finding, it was demonstrated that skeletal muscles
from CAV3 KO mice show abnormalities in the organization of
the T-tubules with dilated and longitudinally oriented T-tubules
[Galbiati et al., 2001].
Although the results of the present investigation do not explain
how the rippling phenomena are induced by passive stretching
and percussion, the finding of reduced E-C coupling efficiency
and reduced Ca
21 influx may explain, at least in part, the
phenotypic characteristics of patients with reduced CAV3 levels.
Interestingly, Lamb [2005] suggested that the induction of
rippling movements may be caused by stretch induced silent
action potentials occurring within the T-tubules of skeletal muscle
fibers. Although possible, it is experimentally very difficult to prove
whether action potentials can escape from T-tubules because
cultured myotubes do not differentiate sufficiently in vitro.
In conclusion, we show that loss of caveolin-3 leads to a
decrease in the E-C coupling efficiency in human myotubes, and
this feature may be one of the underlying causes of the rippling
phenotype seen in patients harboring CAV3 mutations.
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